Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance

Oncology Reports

Volumn 28, Issue 2, 2012, Pages 592-600

  Yang, Lingyun ^a   Li, Ningwei ^a   Wang, Hongjing ^a   Jia, Xibiao ^a   Wang, Xue ^a   Luo, Juan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cisplatin resistance; Expression profiling; microRNA; miR 130a; Ovarian cancer

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 130A; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IC 50; MICROARRAY ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICROARRAY ANALYSIS; MICRORNAS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; SPECTROPHOTOMETRY; TRANSFECTION; UP-REGULATION;

EID: 84863426751     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1823     Document Type: Article

References (44)

1. Legge F, Ferrandina G, Salutari V, et al: Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann Oncol 16: 95-101, 2005.
2. Heintz AP, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95: S161-S192, 2006.
3. Du Bois A and Pfisterer J: Future options for first-line therapy of advanced ovarian cancer. Int J Gynecol Cancer 15: 42-50, 2005. (Pubitemid 40696477)
4. Foster T, Brown TM, Chang J, et al: A review of the current evidence for maintenance therapy in ovarian cancer. Gynecol Oncol 115: 290-301, 2009.
5. de Jongh FE, de Wit R, Verweij J, et al: Dose-dense cisplatin/paclitaxel: a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur J Cancer 38: 2005-2013, 2002.
6. Muggia F: Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 112: 275-281, 2009.
7. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007. (Pubitemid 46137553)
8. Hu M, Liu Y, Deng C, Han R, et al: Enhanced invasiveness in multidrug resistant leukemic cells is associated with overexpression of P-glycoprotein and cellular inhibitor of apoptosis protein. Leuk Lymphoma 52: 1302-1311, 2011.
9. Gottesman MM and Ling V: The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580: 998-1009, 2006. (Pubitemid 43185280)
10. Park E, Gang EJ, Hsieh YT, et al: Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 118: 2191-2199, 2011.
11. Fraser M, Bai T and Tsang BK: Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 122: 534-546, 2008. (Pubitemid 350308944)
12. Cheung CH, Wu SY, Lee TR, et al: Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes. PLoS One 5: e12564, 2010.
13. Zindy P, Bergé Y, Allal B, et al: Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res 71: 4068-4073, 2011.
14. Sabatino MA, Marabese M, Ganzinelli M, et al: Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. Mol Cancer 9: 259, 2010.
15. Kirschner K and Melton DW: Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 30: 3223-3232, 2010.
16. Li Z, Hu S, Wang J, Cai J, et al: MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol 119: 125-130, 2010.
17. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
18. Denli AM, Tops BB, Plasterk RH, et al: Processing of primary microRNAs by the Microprocessor complex. Nature 432: 231-235, 2004. (Pubitemid 39545854)
19. Berezikov E, Guryev V, van de Belt J, et al: Phylogenetic shadowing and computational identification of human microRNA genes. Cell 120: 21-24, 2005. (Pubitemid 40094599)
20. Lund E, Güttinger S, Calado A, et al: Nuclear export of microRNA precursors. Science 303: 95-98, 2004. (Pubitemid 38055779)
21. He L and Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531, 2004. (Pubitemid 38868508)
22. Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450, 2006. (Pubitemid 44430905)
23. Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
24. Iorio MV, Visone R, Di Leva G, et al: MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707, 2007. (Pubitemid 47437445)
25. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006. (Pubitemid 43357945)
26. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529, 2002. (Pubitemid 35403967)
27. Gong C, Yao Y, Wang Y, et al: Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 286: 19127-19137, 2011.
28. Hwang JH, Voortman J, Giovannetti E, et al: Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 5: e10630, 2010.
29. Tomimaru Y, Eguchi H, Nagano H, et al: MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 103: 1617-1626, 2010.
30. Krek A, Grün D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet 37: 495-500, 2005. (Pubitemid 40617277)
31. Grün D, Wang YL, Langenberger D, et al: microRNA target predictions across seven Drosophila species and comparison to mammalian targets. PLoS Comput Biol 1: e13, 2005.
32. Lewis BP, Shih IH, Jones-Rhoades MW, et al: Prediction of mammalian microRNA targets. Cell 115: 787-798, 2003. (Pubitemid 38058492)
33. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005. (Pubitemid 40094598)
34. Kovalchuk O, Filkowski J, Meservy J, et al: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-2159, 2008.
35. Xia L, Zhang D, Du R, et al: MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 123: 372-379, 2008. (Pubitemid 351842022)
36. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005. (Pubitemid 40839735)
37. Pallante P, Visone R, Ferracin M, et al: MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 13: 497-508, 2006. (Pubitemid 43886672)
38. Miller TE, Ghoshal K, Ramaswamy B, et al: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897-29903, 2008.
39. Bhatnagar N, Li X, Padi SK, et al: Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 1: e105, 2010.
40. Wang XC, Tian LL, Wu HL, et al: Expression of miRNA-130a in nonsmall cell lung cancer. Am J Med Sci 340: 385-388, 2010.
41. Chen Y and Gorski DH: Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 111: 1217-1226, 2008. (Pubitemid 351213403)
42. Cui XY, Guo YJ and Yao HR: Analysis of microRNA in drug- resistant breast cancer cell line MCF-7/ADR. Nan Fang Yi Ke Da Xue Xue Bao 28: 1813-1815, 2008 (In Chinese).
43. Naumann RW: The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer. Gynecol Oncol 123: 411-420, 2011.
44. Sherbakova EA, Stromskaia TP, Rybalkina EIu, et al: Role of PTEN protein in multidrug resistance of prostate cancer cells. Mol Biol (Mosk) 42: 487-493, 2008 (In Russian).